AVROBIO EPS Ratio 2011-2026 | AVRO

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio AVROBIO

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
0.27	-2.42	-2.78	-3.31	-2.66	-3.62	-8.38	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
0.27	-8.38	-3.27

Quarterly EPS Ratio AVROBIO

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.02	-1.07	-0.93	-	-1.2	-4.34	-11	-	-7.62	-8.51	-0.57	-	-0.52	-0.64	-0.68	-	-0.75	-0.74	-0.65	-	-1.01	-0.8	-0.77	-	-0.57	-0.67	-0.72	-	-0.49	-2.98	-4.51	-	-2.85	-1.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.49	-11	-2.18

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Adagene ADAG	-0.59	$ 1.65	7.91 %	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	-0.53	$ 3.59	1.99 %	$ 8.64 B	Australia
Arrowhead Pharmaceuticals ARWR	-0.01	$ 66.05	2.3 %	$ 8.83 B	USA
Autolus Therapeutics plc AUTL	-0.86	$ 1.52	-16.3 %	$ 388 M	Britain
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Biogen BIIB	11.2	$ 184.48	-1.67 %	$ 26.9 B	USA
BioNTech SE BNTX	42.2	$ 102.17	2.32 %	$ 27.2 B	Germany
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	0.08	$ 93.52	-1.2 %	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	-0.01	$ 4.25	1.67 %	$ 9.25 B	Israel
BeiGene, Ltd. BGNE	-0.47	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	-0.81	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-1.42	-	-7.31 %	$ 87 M	USA
Bristol-Myers Squibb Company BMY	-4.41	$ 55.71	-0.28 %	$ 113 B	USA
Ascendis Pharma A/S ASND	-8.28	$ 207.49	2.22 %	$ 5 B	Danmark
Codiak BioSciences CDAK	-1.7	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Cerevel Therapeutics Holdings CERE	-2.67	-	-	$ 7.29 B	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Zai Lab Limited ZLAB	-0.26	$ 18.37	-0.97 %	$ 18.2 B	China
Coherus BioSciences CHRS	-2.53	$ 1.61	-5.03 %	$ 152 M	USA
Catalyst Biosciences CBIO	-1.41	$ 10.84	0.46 %	$ 714 M	USA
Caladrius Biosciences CLBS	-2.4	-	-16.75 %	$ 25.8 M	USA
Celldex Therapeutics CLDX	-2.45	$ 25.59	-6.54 %	$ 1.65 M	USA
Cellectis S.A. CLLS	-2.55	$ 4.22	-4.2 %	$ 116 M	France
Clearside Biomedical CLSD	-0.53	-	-	$ 25.3 M	USA
Chimerix CMRX	-0.93	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	-0.09	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	1.35	$ 37.35	-0.4 %	$ 3.86 B	USA
Catalyst Pharmaceuticals CPRX	1.38	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	-2.38	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Crinetics Pharmaceuticals CRNX	-3.69	$ 55.11	3.49 %	$ 4.45 B	USA
CRISPR Therapeutics AG CRSP	-4.34	$ 55.17	2.47 %	$ 4.65 B	Schweiz
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Zentalis Pharmaceuticals ZNTL	-4.47	$ 3.53	-5.75 %	$ 231 M	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	3.29	$ 29.43	6.09 %	$ 1.43 B	USA